profit from every €100 of sales.
€0€100
DiaSorin
€85.50+3.46% today
+32.9% since Dec 19, 25
1-year low €55.621-year high €85.50
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €27.07 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What DiaSorin sold, what it kept, and what it did with the cash.
Sales went from €1.36 billion in 2022 to €1.20 billion in 2025, with €156 million of profit last year.
SalesProfit
DiaSorin handed back 31% of the cash it generated last year.
€64M
Free cash flow 2025€205M
Bought back its own shares–
Paid as dividends€64M
Cash vs. debt€166M vs. €791M
DiaSorin vs. similar companies
DiaSorin grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| DiaSorin | 27.1× · Fair price | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.2× · Expensive | ||
 Waters | 141.4× · Very expensive | ||
 WuXi AppTec | 27.1× · Fair price |
AI analysis
An AI analyst reads DiaSorin's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,361 | 1,148 | 1,185 | 1,195 | |
| 901 | 741 | 782 | 773 | |
| 375 | 238 | 265 | 270 | |
| 514 | 367 | 399 | 364 | |
| 241 | 160 | 188 | 156 | |
| 4.15 | 2.87 | 3.47 | 2.83 | |
| 66.2% | 64.6% | 65.9% | 64.7% | |
| 27.6% | 20.7% | 22.4% | 22.6% | |
| 17.7% | 13.9% | 15.9% | 13.0% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,408 | 3,211 | 3,305 | 2,873 |
| Cash | 242 | 280 | 344 | 166 |
| Total debt | 1,352 | 1,193 | 1,014 | 791 |
| Total liabilities | 1,888 | 1,673 | 1,506 | 1,296 |
| 1,519 | 1,539 | 1,801 | 1,584 | |
| 58 | 56 | 54 | 53 | |
| 9.5% | 6.4% | 7.3% | 7.6% | |
| 15.9% | 10.4% | 10.4% | 9.8% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 389 | 312 | 359 | 343 | |
| 114 | 113 | 120 | 138 | |
| 276 | 198 | 239 | 205 | |
| Dividends paid | 57 | 59 | 61 | 64 |
| – | – | – | – | |
| 10 | 10 | 11 | 11 |
Valuation
- 27.1×
- –
- –
- 2.1×
- 3.5×
- 20.5×
- 13.3×
- 4.9%
- 3.7%
- 1.5%
Profitability
- 64.7%
- 22.6%
- 13.0%
- –
- 7.6%
- 7.7%
- –
- –
- –
- –
Growth
- −4.2%
- −12.0%
- –
- –
- −3.0%
Financial health
- 1.7×
- 0.50
- –
- 9.6×
- 1.55
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 41%of 952
Top 19%of 883
Top 49%of 576
Bottom 10%of 870
Top 22%of 985
1.5%of the share price, paid each year
On $1,000 invested$15a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
40.8% of its profit
Room to growStretchedMore than it earns: 31.0%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
54No pass
Philip Fisher
51No pass
Peter Lynch
24No pass
Joel Greenblatt
22No pass
Charlie Munger
50No pass
Terry Smith
46No pass
Questions about DiaSorin
Is DiaSorin a good stock to buy?
A solid business at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the DiaSorin AI analysis
What does DiaSorin do?
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It is in Diagnostics & Research, based in Saluggia, VC, Italy, with 3,212 employees.
Does DiaSorin pay a dividend?
Yes. At today's price the dividend is 1.5% a year, about 41% of its yearly profit. In 2025 it paid out €63.5 million in dividends.
Is DiaSorin stock halal?
Yes. DiaSorin passes our halal screen: its business is permitted and its debt is 19% of its market value, under the 30% limit. How we check
Who are DiaSorin's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with DiaSorin's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.